ArticleThe Eurasian journal of medicine2024
Protective Effects of Oxyresveratrol in IsoproterenolInduced Myocardial Infarction in Rats: A Stereological Study.
Article in The Eurasian journal of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study is to examine the protective effect of oxyresveratrol (OXY) against isoproterenol-induced myocardial infarction in rats, through routine biochemical parameters and oxidative stress parameters that show heart damage. Oxyresveratrol was administered by oral gavage at doses of 10 and 20 mg/kg, respectively, once a day for 5 days. On the fourth and fifth days, 180 mg/kg isoproterenol was administered intraperitoneally to the OXY treatment group and control groups. Twenty-four hours after the last isoproterenol application, blood and heart tissue were taken under anesthesia and transferred to -80 degrees and formalin for biochemical and histopathological studies. CK-MB and TnI levels were measured in serum obtained from blood. In the heart tissue, antioxidant parameters, superoxide dismutase (SOD), glutathione (GSH) and malondialdehyde (MDA) levels, and histopathological and stereological evaluations were performed. Oxyresveratrol has antioxidant and anti-inflammatory activity depending on the dose. Oxyresveratrol showed potent protective effect against isoproterenol-induced myocardial infarction. It has been proven that at all doses of oxyresveratrol, statistically, isoproterenol decreased the MDA level, which was one of the oxidative stress markers, compared to the control group, and increased SOD activity and GSH levels. Similar to the biochemically determined parameters, oxyresveratrol treatment was also found to have a protective effect at the cell level, histopathologically and stereologically. All results show that oxyresveratrol has strong antioxidant and anti-inflammatory activity, especially at a dose of 20 mg/kg, it significantly reduces myocardial damage and this agent has a cardioprotective effect.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.